Trends in novel antiandrogen receptor signal inhibitor use and medical costs in prostate cancer
ARSI usage and medical costs associated with prostate cancer increased significantly from 2016 to 2021. Despite the limited use of ARSIs, a considerable proportion of the medical costs for prostate cancer-specific agents had been spent on ARSIs.
Authors
- Noritaka Ishi
- Shingo Hatakeyama (ORCID: https://orcid.org/0000-0002-0026-4079)
- Teppei Okamoto (ORCID: https://orcid.org/0000-0002-3750-3811)
- Naoki Fujita (ORCID: https://orcid.org/0000-0001-8284-9582)
- Takuya Oishi (ORCID: https://orcid.org/0000-0001-7411-8237)
- Kyo Togashi
- Tomoko Hamaya
- Hikari Miura
- Fumiya Yoneyama (ORCID: https://orcid.org/0000-0001-6862-0087)
- Chikara Οhyama (ORCID: https://orcid.org/0000-0003-1550-8379)
- Yoshiharu Okuyama
- Ryuma Tanaka (ORCID: https://orcid.org/0000-0002-0132-052X)
- Hayato Yamamoto
Institutions
- Hirosaki University (JP)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1002/cam4.70226
- Citations
- 6
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 2.51